SOURCE: Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals, Inc.

October 26, 2009 08:30 ET

Molecular Insight Pharmaceuticals, Inc. to Report Third Quarter Financial Results on November 9, 2009

CAMBRIDGE, MA--(Marketwire - October 26, 2009) - Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced it will report third quarter 2009 financial results on November 9, 2009.

Following the release of the financial results, the Company will host a conference call during which Molecular Insight management will discuss the financial results and operating highlights for the quarter at 4:30 p.m. Eastern Time.

Conference Call Details

To access the call on November 9, 2009 at 4:30 p.m., dial 1-888-713-4214 (or 1-617-213-4866 for international participants) at least five minutes prior to the start of the call. The participant pass code is 53802606. For one week following the call, an audio replay can be accessed by dialing 1-888-286-8010 (or 1-617-801-6888 for international callers) and using the pass code 47943423.

An audio webcast of the call will also be available in the "Investor Relations" section of the Company's website, for 30 days after the call.

About Molecular Insight Pharmaceuticals, Inc.

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and is a pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of targeted therapeutic and molecular imaging radiopharmaceuticals, primarily for use in oncology. Molecular Insight has five clinical-stage candidates in development. The lead oncology candidate, Azedra™, is currently in a pivotal trial for pheochromocytoma. Onalta™ is being developed for the treatment of carcinoid and other neuroendocrine tumors, Solazed™ for treatment of malignant metastatic melanoma, and Trofex™ for detecting metastatic prostate cancer. Zemiva™ is being developed for the diagnosis of acute myocardial ischemia. For further information on Molecular Insight Pharmaceuticals, please visit

Contact Information